Expand Program on Immunization, Chongqing Center for Disease Control and Prevention, Chongqing, China.
Medicine (Baltimore). 2024 Oct 18;103(42):e40075. doi: 10.1097/MD.0000000000040075.
The study aimed to explore the influencing factors after 2 doses of inactivated COVID-19 vaccines (Sinopharm/BBIBP-CorV) in the real world. We conducted a cross-sectional serological study involving 316 volunteers aged ≧ 18 years from 7 vaccination hospitals in the Yubei districts, Yuzhong districts, and Jiulongpo districts of Chongqing. Serum samples were obtained about 1 month after 2 dose vaccination, and Nabs were tested using the pseudovirus-based neutralizing assay. Chi-square or Fisher exact tests were used to analyze the seropositive rates, while the Kruskal-Wallis H or Mann-Whitney U tests were used to analyze differences in Nabs level among stratified groups. Logistic regression analyses were conducted to identify the influencing factors. The results showed that seropositive rates was 76.27% and the GMT was 26.13 (95% CI: 23.03-29.66) after 2 doses of COVID-19 inactivated vaccination. The risk of being seropositive in 18 to 29, 30 to 39, 40 to 49, 50 to 59, and 60 to 69 years were 12.808-fold, 8.041-fold, 7.818-fold, 6.275-fold, 1.429-fold compared with the people aged ≥ 70 years (P < .05), and the risk of being seropositive of intervals 15 to 21 and 22 to 28 days were 0.273-fold and 0.286-fold compared with >28 days (P < .05), respectively. In conclusion, age may be a risk factor for reduced antibody production, and longer vaccination intervals-may be a protective factor that increases antibody production. These findings contribute to informing future vaccination strategies.
本研究旨在探索 2 剂灭活 COVID-19 疫苗(国药/BBIBP-CorV)在真实世界中的影响因素。我们进行了一项横断面血清学研究,纳入了来自重庆市渝北区、渝中区和九龙坡区的 7 家接种医院的 316 名年龄≥18 岁的志愿者。在 2 剂接种后约 1 个月采集血清样本,并使用假病毒中和测定法检测 Nabs。采用卡方检验或 Fisher 确切检验分析血清阳性率,采用 Kruskal-Wallis H 检验或 Mann-Whitney U 检验分析分层组中 Nabs 水平的差异。采用 logistic 回归分析识别影响因素。结果显示,2 剂 COVID-19 灭活疫苗接种后的血清阳性率为 76.27%,GMT 为 26.13(95%CI:23.03-29.66)。18-29、30-39、40-49、50-59 和 60-69 岁人群的血清阳性风险分别是≥70 岁人群的 12.808 倍、8.041 倍、7.818 倍、6.275 倍和 1.429 倍(P<.05),间隔 15-21 天和 22-28 天接种的血清阳性风险分别是间隔>28 天的 0.273 倍和 0.286 倍(P<.05)。总之,年龄可能是抗体产生减少的危险因素,较长的接种间隔可能是增加抗体产生的保护因素。这些发现有助于为未来的疫苗接种策略提供信息。